Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 3

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease

Pages
751–757
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Decision of usage of RAAS blockade should be made based on the risk and benefit ratio

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hypertension and proteinuria are well-known predictors of chronic kidney disease (CKD) progression.
📊
Key Findings & Data:Forty (28 female) patients with chronic kidney diseases were collected from nephrology outpatient clinic, internal medicine department, Beni Suef University hospital.
💡
Conclusion & Impact:Decision of usage of RAAS blockade should be made based on the risk and benefit ratio
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hypertension and proteinuria are well-known predictors of chronic kidney disease (CKD) progression. Therapeutic interventions have different magnitude of albuminuria and hypertension. This study was designed to evaluate the efficacy and safety of combined vs. single renin-angiotensin-aldosterone system (RAAS) blockade in chronic kidney disease. Forty (28 female) patients with chronic kidney diseases were collected from nephrology outpatient clinic, internal medicine department, Beni Suef University hospital. They were divided randomly into 2 groups. Group A was 24 (20 females) patients treated with Enalapril, as angiotensin converting enzyme inhibitor (ACE-I) alone. Group B was 16 (8 females) patients treated with combination of Enalapril and Irbesartan, as angiotensin receptor blocker (ARB). All patients were subjected to full history taking; thorough clinical examination; certain laboratory tests and renal function tests at the start of the study, 1.5 and 3 months later. Proteinuria, urinary albumin/creatinine ratio (UACR), systolic blood pressure (SBP) and glomerular filtration rate (GFR) were significantly (p<0.001) decreased with dual therapy (ACE-I and ARB) compared to monotherapy. In return serum potassium level (Ser.K), serum creatinine level (Ser.Cr) were significantly increased (p<0.001) with dual therapy (ACE-I and ARB) compared to monotherapy. The hypotensive and antiproteinuric effect of RAAS inhibitors should be compared with hyperkalemia and rise in serum creatinine level when prescribed as monothrapy or combination in patients with CKD. Decision of usage of RAAS blockade should be made based on the risk and benefit ratio

🔖

Cite This Article

ABDELRAHMAN, M. A., GENİNA, A., SAİD, A. S. A., ABDELRAHİ, M. E. A. (2016). Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease. Medicine Science, Cilt: 5 - Sayı: 3, 751–757. https://ajindex.com/articles/277500

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-100
  2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47
  3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-47
  4. Haynes R, Mason P, Rahimi K and Landray MJ. Dual blockade of the renin–angiotensin system: are two better than one? Nephrol Dial Transplant. 2009:458
  5. Kunz R, Friedrich C, Wolbers M, and Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008; 148(1): 30-48
  6. Schieppati A and Remuzzi G. The future of renoprotection: frustration and promises. Kidney Int Suppl. 2003;64(6):1947-55
  7. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of reninangiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;68:57-65
  8. Pichler RH. and de Boer I.H. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Curr Diab Rep. 2010;10(4) 297-305
  9. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single renin– angiotensin–aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens. 2013;26(3):424-41
  10. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. AJKD. 2013;62(2):201-13
  11. James PA, Oparil S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507-20
  12. Molitch ME, Adler AI, F